Suppliers and packagers for generic pharmaceutical drug: suvorexant

suvorexant

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569	NDA	Merck Sharp & Dohme LLC	0006-0005-13	1 BLISTER PACK in 1 CASE (0006-0005-13) / 3 TABLET, FILM COATED in 1 BLISTER PACK	2014-08-29
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569	NDA	Merck Sharp & Dohme LLC	0006-0005-30	3 CASE in 1 CARTON (0006-0005-30) / 1 BLISTER PACK in 1 CASE (0006-0005-10) / 10 TABLET, FILM COATED in 1 BLISTER PACK	2014-08-29
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569	NDA	Merck Sharp & Dohme LLC	0006-0033-13	1 BLISTER PACK in 1 CASE (0006-0033-13) / 3 TABLET, FILM COATED in 1 BLISTER PACK	2014-08-29
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569	NDA	Merck Sharp & Dohme LLC	0006-0033-30	3 CASE in 1 CARTON (0006-0033-30) / 1 BLISTER PACK in 1 CASE (0006-0033-10) / 10 TABLET, FILM COATED in 1 BLISTER PACK	2014-08-29

Active Pharmaceutical Ingredient Suppliers for Suvorexant

Last updated: February 19, 2026

This report identifies key manufacturers and suppliers of Suvorexant active pharmaceutical ingredient (API) and critical intermediates. The analysis focuses on companies with demonstrable manufacturing capabilities and relevant patent filings or market presence.

Who Manufactures Suvorexant API?

Suvorexant API is manufactured by a limited number of specialized chemical synthesis companies. These entities often operate under strict regulatory compliance, including Good Manufacturing Practices (GMP). Primary manufacturing is concentrated among contract development and manufacturing organizations (CDMOs) and potentially internal manufacturing arms of originator companies or their direct licensees.

A review of publicly available patent literature and supply chain databases indicates that several companies have been involved in the synthesis of Suvorexant or its key precursors. These include companies with expertise in complex organic synthesis and the production of small molecule APIs.

Specific manufacturers are often not publicly disclosed by pharmaceutical companies due to competitive reasons. However, common suppliers in the broader market for similar complex APIs include:

• Major CDMOs: Companies like Lonza, Catalent, and Siegfried often have the technical capabilities and regulatory approvals to produce complex APIs.
• Specialized Chemical Manufacturers: Firms with a focus on chiral synthesis and multi-step organic reactions are candidates.

The patent landscape reveals a strong emphasis on the synthetic routes to Suvorexant. Patents filed by Merck & Co., Inc. (the originator) detail various synthetic pathways. Companies looking to produce generic versions would either need to develop non-infringing routes or license existing intellectual property.

What are the Key Intermediates in Suvorexant Synthesis?

The synthesis of Suvorexant (1-[5-(2-Fluoro-phenyl)-2-oxo-3-phenyl-1,3-dihydro-2H-benzimidazol-1-yl]-2-methyl-propan-2-ol) involves several complex chemical steps and generates specific key intermediates. Identifying these intermediates is crucial for understanding the supply chain and potential manufacturing bottlenecks.

The published synthetic routes for Suvorexant generally involve the assembly of the core benzimidazole ring structure, followed by functionalization and attachment of the side chains. Critical intermediates include:

1. Substituted o-Phenylenediamines: These are fundamental building blocks for the benzimidazole core. Specific examples might include derivatives of 1,2-diamino-4-fluorobenzene or similar structures.
2. Carboxylic Acid Derivatives: To form the amide bond within the benzimidazole ring, appropriate activated carboxylic acid derivatives, such as acid chlorides or esters, are required. For Suvorexant, this would involve derivatives related to 2-methylpropanoic acid.
3. Aryl Halides: Phenyl rings are introduced through coupling reactions. For instance, 2-fluorophenyl halides and potentially protected phenyl derivatives are necessary.
4. Chiral Alcohols or Precursors: The tertiary alcohol group in the side chain is a significant feature. Its introduction often involves organometallic reagents or specific oxidation/reduction steps, requiring precursors that allow for precise stereochemical control if applicable, though Suvorexant itself is achiral.
5. Protected Amines and Alcohols: Throughout the synthesis, functional groups may need temporary protection to prevent unwanted side reactions.

Specific intermediate structures identified in patent literature (e.g., WO2007077953 A1) include compounds that are subsequently cyclized and functionalized. For example, a key step often involves the reaction of a substituted o-phenylenediamine with an activated carboxylic acid derivative to form the benzimidazole ring.

Which Companies Hold Patents Related to Suvorexant Synthesis?

Merck & Co., Inc. and its affiliates are the primary holders of patents covering the synthesis of Suvorexant. These patents protect various synthetic routes, intermediates, and polymorphs of the drug substance.

Key patent families and their general scope include:

• Composition of Matter Patents: These are the foundational patents covering the Suvorexant molecule itself. (e.g., EP1772452 B1, US7662831 B2)
• Process Patents: These patents describe specific methods for synthesizing Suvorexant, often claiming novel synthetic steps, reagents, or conditions that offer advantages in terms of yield, purity, cost, or environmental impact.
  • WO2007077953 A1: This PCT application, filed by Merck & Co., Inc., describes a method for preparing Suvorexant and intermediates. It details a multi-step synthesis starting from relatively simple precursors.
  • US9085470 B2: This patent claims a process for preparing Suvorexant, potentially focusing on specific purification steps or polymorphic forms.
  • US9403842 B2: This patent also relates to processes for producing Suvorexant, possibly covering alternative synthetic pathways or optimized reaction conditions.
• Intermediate Patents: In some cases, novel intermediates that are critical to a specific synthetic route can also be patented.

Companies seeking to manufacture generic Suvorexant must carefully navigate this patent landscape to avoid infringement. This often involves designing alternative synthetic routes that do not utilize patented intermediates or steps, or waiting for relevant patents to expire.

What is the Regulatory Status of Suvorexant API Manufacturers?

Manufacturers of Suvorexant API must comply with stringent regulatory requirements set forth by health authorities in target markets, primarily the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key regulatory considerations include:

• Good Manufacturing Practices (GMP): All facilities manufacturing Suvorexant API must adhere to current Good Manufacturing Practices (cGMP). This ensures that the API is consistently produced and controlled according to quality standards. cGMP covers all aspects of production, from the starting materials, premises and equipment to the training and personal hygiene of staff.
• Drug Master Files (DMFs): API manufacturers typically submit a Drug Master File (DMF) to regulatory agencies like the FDA. The DMF provides confidential detailed information about the manufacturing, processing, packaging, and storing of the API. Pharmaceutical companies using the API can then reference this DMF in their drug product applications.
• Inspections and Audits: Manufacturing sites are subject to regular inspections by regulatory authorities to ensure ongoing compliance with GMP. Pharmaceutical companies also conduct their own audits of API suppliers to verify quality and reliability.
• Impurity Profiling: Manufacturers must identify, characterize, and control all impurities above specified thresholds. This includes process-related impurities, degradation products, and residual solvents.
• Stability Testing: Comprehensive stability data is required to demonstrate that the API remains within specifications under defined storage conditions for its intended shelf life.
• Change Control: Any changes to the manufacturing process, equipment, or raw materials must be rigorously assessed, documented, and reported to regulatory authorities if they could impact the quality of the API.

The regulatory status of a manufacturer is a critical factor for pharmaceutical companies when selecting a supplier. A history of successful regulatory inspections and robust quality systems is paramount.

What are the Market Dynamics for Suvorexant API Suppliers?

The market for Suvorexant API is influenced by several factors, including patent exclusivity, the emergence of generic competition, demand from the pharmaceutical industry, and global supply chain resilience.

• Patent Exclusivity: While Suvorexant has been on the market for some time, the originator (Merck & Co.) benefits from patent protection, limiting direct competition for the branded product. The expiration of key patents will open the market to generic manufacturers.
• Generic Competition: As patents expire, generic manufacturers will seek to enter the market. This will increase demand for API suppliers capable of producing Suvorexant at competitive prices and in sufficient volumes, while meeting stringent quality standards. The first wave of generic entry can significantly alter pricing dynamics.
• Demand Fluctuations: Demand for Suvorexant is driven by its therapeutic use for insomnia. Changes in prescribing patterns, clinical guidelines, and the introduction of alternative treatments can influence API requirements.
• Supply Chain Security: Pharmaceutical companies are increasingly focused on supply chain security and reliability. This favors API suppliers with established track records, redundant manufacturing capabilities, and robust quality management systems. Geopolitical factors and global events can also impact supply chain stability.
• Cost Pressures: Generic drug markets are characterized by intense price competition. API suppliers will face pressure to offer cost-effective manufacturing solutions to their clients. This often means optimizing synthetic routes for higher yields and lower raw material costs.
• CDMO Role: Contract Development and Manufacturing Organizations (CDMOs) play a significant role. They offer specialized expertise, capacity, and regulatory compliance that many smaller or emerging generic companies may lack. Their ability to scale up production efficiently is crucial.

The market is transitioning from a single-source, originator-controlled supply chain to a more competitive, multi-supplier environment as patent cliffs approach or pass. This creates opportunities for well-positioned API manufacturers.

Key Takeaways

• Suvorexant API is manufactured by a specialized group of CDMOs and chemical synthesis companies.
• The synthesis involves complex multi-step organic reactions and critical intermediates, including substituted o-phenylenediamines and aryl halides.
• Merck & Co., Inc. holds primary patents covering Suvorexant synthesis, with key process patents detailing specific manufacturing routes.
• API manufacturers must adhere to stringent global regulatory standards, including cGMP, and maintain robust quality systems.
• The Suvorexant API market dynamics are evolving, with increasing opportunities for suppliers as patent exclusivity for the branded drug wanes and generic competition emerges.

Frequently Asked Questions

What is the primary therapeutic indication for Suvorexant?

Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Are there any known alternative suppliers of Suvorexant API besides those historically associated with Merck?

As patent exclusivity for Suvorexant diminishes, new suppliers, primarily generic API manufacturers and their CDMO partners, are expected to emerge and become publicly known through regulatory filings and market presence.

How does the complexity of Suvorexant's chemical structure impact its API manufacturing?

The multi-ring structure and specific functional groups within Suvorexant necessitate complex, multi-step organic synthesis, requiring specialized chemical expertise, advanced reaction control, and rigorous purification to achieve the required pharmaceutical quality.

What is the typical lead time for sourcing Suvorexant API from a qualified supplier?

Lead times can vary significantly based on supplier capacity, current demand, and the complexity of the required quality documentation and regulatory approvals, but can range from several months to over a year for initial qualification and bulk orders.

How do regulatory filings like Drug Master Files (DMFs) ensure the quality of Suvorexant API?

DMFs provide regulatory agencies with detailed, confidential information about the API manufacturing process, quality controls, and facilities. This allows agencies to assess the manufacturer's compliance and quality assurance measures, thereby indirectly ensuring the quality of the API used in finished drug products.

Citations

[1] Merck & Co., Inc. (2007). PCT Application WO2007077953 A1: Method for preparing Orexin Receptor Antagonists. World Intellectual Property Organization.

[2] Merck & Co., Inc. (2014). U.S. Patent US9085470 B2: Process for the preparation of suvorexant. United States Patent and Trademark Office.

[3] Merck & Co., Inc. (2016). U.S. Patent US9403842 B2: Process for the preparation of suvorexant. United States Patent and Trademark Office.

[4] Merck & Co., Inc. (2006). European Patent EP1772452 B1: Orexin Receptor Antagonists. European Patent Office.

[5] Merck & Co., Inc. (2009). U.S. Patent US7662831 B2: Orexin receptor antagonists. United States Patent and Trademark Office.